Alzheimer’s Disease Trials (AD)


The following are ongoing Alzheimer’s Disease clinical trials carried out at various C5R sites involving participants with Alzheimer’s disease.


Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer’s Disease (COGNITE)


Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer’s Disease (MK-4305-061)


A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease


Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type


A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease_ (MissionAD2)


A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S1)


Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)


A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease


Brain Imaging and Safety Study Evaluating TRx0237 in Subjects With Mild Alzheimer’s Disease


A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S2)


BI 425809 in Patients With Cognitive Impairment Due to Alzheimer’s Disease.


A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ)


A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer’s Disease